Metabolomics and surgical oncology: Potential role for small molecule biomarkers

Journal of Surgical Oncology

Volumn 103, Issue 5, 2011, Pages 451-459

  Davis, Vanessa W ^a   Bathe, Oliver F ^b   Schiller, Daniel E ^a   Slupsky, Carolyn M ^c   Sawyer, Michael B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Personalized cancer care; Screening and diagnosis; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CHOLINE; GLYCINE; IMATINIB; PHOSPHORYLCHOLINE;

CANCER DIAGNOSIS; CANCER RESEARCH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; EARLY DIAGNOSIS; GAS CHROMATOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; PERSONALIZED MEDICINE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR MICROENVIRONMENT;

COLORECTAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; METABOLOMICS; SPECIALTIES, SURGICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 79952601264     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21831     Document Type: Review

References (71)

1. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-1189.
2. Denkert C, Budczies J, Kind T, et al.: Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-10804. (Pubitemid 44876975)
3. Lahner B, Gong J, Mahmoudian M, et al.: Genomic scale profiling of nutrient and trace elements in Arabidopsis thaliana. Nat Biotechnol 2003;21:1215-1221. (Pubitemid 37186179)
4. van Ravenzwaay B, Cunha GC, Leibold E, et al.: The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 2007;172:21-28. (Pubitemid 47161053)
5. Goodacre R: Metabolomics of a superorganism. J Nutr 2007; 137:259S-266S.
6. Lindon JC, Holmes E, Nicholson JK: So what's the deal with metabonomics? Anal Chem 2003;75:384A-391A.
7. Di Leo A, Claudino W, Colangiuli D, et al.: New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 2007;18:xii8-xii14.
8. Ryals J: Metabolomics: An important emerging science. Journal [serial on the Internet]. 2004 Date: Available from: http://www.touchbriefings.com.
9. Nordstrom A, Lewensohn R: Metabolomics: Moving to the clinic. J Neuroimmune Pharmacol 2009;5:4-17.
10. Garg U, Dasouki M: Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: Clinical and laboratory aspects. Clin Biochem 2006;39:315-332.
11. Spratlin JL, Serkova NJ, Eckhardt SG: Clinical applications of metabolomics in oncology: A review. Clin Cancer Res 2009;15:431-440.
12. Lindon JC, Holmes E, Nicholson JK: Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 2004;4:189-199. (Pubitemid 38327248)
13. Claudino WM, Quattrone A, Biganzoli L, et al.: Metabolomics: Available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-2846. (Pubitemid 47123194)
14. Kim YS, Maruvada P, Milner JA: Metabolomics in biomarker discovery: Future uses for cancer prevention. Future Oncol 2008;4:93-102. (Pubitemid 351372610)
15. Beckonert O, Keun HC, Ebbels TM, et al.: Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007;2:2692-2703.
16. Castle AL, Fiehn O, Kaddurah-Daouk R, et al.: Metabolomics Standards Workshop and the development of international standards for reporting metabolomics experimental results. Brief Bioinform 2006;7:159-165. (Pubitemid 44404882)
17. Lenz EM, Bright J, Wilson ID, et al.: A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 2003;33:1103-1115. (Pubitemid 37501013)
18. Reo NV: NMR-based metabolomics. Drug Chem Toxicol 2002;25:375-382.
19. Issaq HJ, Nativ O,Waybright T, et al.: Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 2008;179:2422-2426.
20. Gao H, Dong B, Liu X, et al.: Metabonomic profiling of renal cell carcinoma: High-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 2008;624:269-277.
21. Perroud B, Lee J, Valkova N, et al.: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64.
22. Yang J, Xu G, Zheng Y, et al.: Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B: Analyt Technol Biomed Life Sci 2004;813:59-65. (Pubitemid 39535429)
23. Ma YL, Qin HL, Liu WJ, et al.: Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig Dis Sci 2009;54:2655-2662.
24. Yan SK, Wei BJ, Lin ZY, et al.: A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol 2008;44:477-483.
25. Tiziani S, Lopes V, Gunther UL: Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 2009;11:269-276, 4p following
26. Frickenschmidt A, Frohlich H, Bullinger D, et al.: Metabonomics in cancer diagnosis: Mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers 2008;13:435-449. (Pubitemid 351865818)
27. Osl M, Dreiseitl S, Pfeifer B, et al.: A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 2008;24:2908-2914.
28. Odunsi K, Wollman RM, Ambrosone CB, et al.: Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005;113:782-788. (Pubitemid 40101260)
29. Woo HM, Kim KM, Choi MH, et al.: Mass spectrometry based metabolomic approaches in urinary biomarker study of women's cancers. Clin Chim Acta 2009;400:63-69.
30. Van QN, Veenstra TD: How close is the bench to the bedside? Metabolic profiling in cancer research. Genome Med 2009;1:5.
31. Goodacre R, Vaidyanathan S, Dunn WB, et al.: Metabolomics by numbers: Acquiring and understanding global metabolite data. Trends Biotechnol 2004;22:245-252. (Pubitemid 38515742)
32. Mazurek S, Eigenbrodt E: The tumor metabolome. Anticancer Res 2003;23:1149-1154. (Pubitemid 36750932)
33. Dettmer K, Aronov PA, Hammock BD: Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007;26:51-78. (Pubitemid 46051813)
34. Dunn WB, Bailey NJ, Johnson HE: Measuring the metabolome: Current analytical technologies. Analyst 2005;130:606-625. (Pubitemid 40685888)
35. Robertson DG: Metabonomics in toxicology: A review. Toxicol Sci 2005;85:809-822.
36. Fan W: Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures. Prog NMR Spectrosc 1996;28:161-219.
37. Nicholson JK, Foxall PJ, Spraul M, et al.: 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995;67:793-811.
38. Pretsch E, Seibl J, Simon W, et al.: Structure determination of organic compounds: Tables of spectral data. Berlin: Springer-Verlag; 1989.
39. Kell DB, Mendes P: Snapshots of systems - Metabolic control analysis and biotechnology in the post-genomic era. In: Cornish-Bowden A, Cardinas ML, editors. Technological and medical implications of metabolic control analysis. Netherlands: Kluwer Academic Publishers; 2000. pp. 3-25.
40. Wishart DS, Tzur D, Knox C, et al.: HMDB: The human metabolome database. Nucleic Acids Res 2007;35:D521-D526. (Pubitemid 46056263)
41. Bathen TF, Jensen LR, Sitter B, et al.: MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2007;104:181-189. (Pubitemid 47086272)
42. Sitter B, Lundgren S, Bathen TF, et al.: Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006;19:30-40. (Pubitemid 43250787)
43. Mountford CE, Somorjai RL, Malycha P, et al.: Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br J Surg 2001;88:1234-1240. (Pubitemid 34015609)
44. Chan EC, Koh PK, Mal M, et al.: Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009;8:352-361.
45. Denkert C, Budczies J, Weichert W, et al.: Metabolite profiling of human colon carcinoma - Deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008;7:72.
46. Monleon D, Morales JM, Barrasa A, et al.: Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 2009;22:342-348.
47. Cheng LL, Burns MA, Taylor JL, et al.: Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005;65:3030-3034. (Pubitemid 40524579)
48. Scheidler J, Hricak H, Vigneron DB, et al.: Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging - Clinicopathologic study. Radiology 1999;213:473-480. (Pubitemid 29510595)
49. Sitter B, Sonnewald U, Spraul M, et al.: High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002;15:327-337. (Pubitemid 34960100)
50. Kvistad KA, Bakken IJ, Gribbestad IS, et al.: Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999;10:159-164. (Pubitemid 29362430)
51. Le Borgne J, de Calan L, Partensky C: Cystadenomas and cystadenocarcinomas of the pancreas: A multiinstitutional retrospective study of 398 cases. French Surgical Association. Ann Surg 1999;230:152-161. (Pubitemid 30191880)
52. Bartella L, Thakur SB, Morris EA, et al.: Enhancing nonmass lesions in the breast: Evaluation with proton (1H) MR spectroscopy. Radiology 2007;245:80-87. (Pubitemid 47417790)
53. Jacobs MA, Barker PB, Bottomley PA, et al.: Proton magnetic resonance spectroscopic imaging of human breast cancer: A preliminary study. J Magn Reson Imaging 2004;19:68-75. (Pubitemid 38055731)
54. Bartella L, Huang W: Proton (1H) MR spectroscopy of the breast. Radiographics 2007;27:S241-S252.
55. Gayed I, Vu T, Iyer R, et al.: The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17-21. (Pubitemid 47611603)
56. Holdsworth CH, Badawi RD, Manola JB, et al.: CTand PET: Early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol 2007;189:W324-W330.
57. Katz-Brull R, Lavin PT, Lenkinski RE: Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002;94:1197-1203. (Pubitemid 34993869)
58. Huang W, Fisher PR, Dulaimy K, et al.: Detection of breast malignancy: Diagnostic MR protocol for improved specificity. Radiology 2004;232:585-591. (Pubitemid 38971303)
59. Kaplan RS: Complexities, pitfalls, and strategies for evaluating brain tumor therapies. Curr Opin Oncol 1998;10:175-178.
60. Jagannathan NR, Kumar M, Seenu V, et al.: Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001;84:1016-1022. (Pubitemid 32448495)
61. Meisamy S, Bolan PJ, Baker EH, et al.: Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo (1)H MRspectroscopy - A pilot study at 4 T. Radiology 2004;233:424-431.
62. Rieber A, Brambs HJ, Gabelmann A, et al.: Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002;12:1711-1719. (Pubitemid 36940255)
63. Qiu Y, Cai G, Su M, et al.: Urinary metabonomic study on colorectal cancer. J Proteome Res 9:1627-1634.
64. Jordan KW, Nordenstam J, Lauwers GY, et al.: Metabolomic characterization of human rectal adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis Colon Rectum 2009;52:520-525.
65. Kroemer G, Pouyssegur J: Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008;13:472-482. (Pubitemid 351766797)
66. Otani Y, Furukawa T, Yoshida M, et al.: Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139:484-492.
67. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58. (Pubitemid 30043939)
68. Holmes E, Antti H: Chemometric contributions to the evolution of metabonomics: Mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 2002;127:1549-1557. (Pubitemid 36020854)
69. Pan Z, Raftery D: Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007;387:525-527. (Pubitemid 46067468)
70. Chemical MSI, Analysis WG: [cited]; Available from: http://msiworkgroups. sourceforge.net/chemical-analysis/.
71. German JB, Hammock BD,Watkins SM: Metabolomics: Building on a century of biochemistry to guide human health. Metabolomics 2005;1:3-9.